Catalog No.
DHC98801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13612
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AN 100226, BG00002, CAS: 189261-10-7
Clone ID
Natalizumab
Natalizumab in Multiple Sclerosis: Long-Term Management, PMID: 28468254
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies, PMID: 31589278
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring, PMID: 33072089
Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial, PMID: 32591475
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing, PMID: 31515290
A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis, PMID: 30639651
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP), PMID: 32234967
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension, PMID: 29545067
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients, PMID: 32056253
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial, PMID: 32690785
The risk of PML from natalizumab, PMID: 30784548
Natalizumab-Associated Primary Central Nervous System Lymphoma, PMID: 28962961
Natalizumab in relapsing-remitting multiple sclerosis, PMID: 27008031
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis, PMID: 26835603
Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker, PMID: 32156774
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study, PMID: 28209331
The role of natalizumab in the treatment of multiple sclerosis, PMID: 20615052
Use of natalizumab in multiple sclerosis: current perspectives, PMID: 27413840
Natalizumab treatment of multiple sclerosis: new insights, PMID: 28004598
Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology, PMID: 28167648
Natalizumab-associated progressive multifocal leukoencephalopathy in Germany, PMID: 30952796
Natalizumab: a new therapy for acute ischemic stroke?, PMID: 27476862
[Natalizumab treatment in multiple sclerosis], PMID: 26156254
Natalizumab induced cutaneous sarcoidosis-like reaction, PMID: 31108403
Natalizumab in secondary progressive multiple sclerosis, PMID: 29545068
Treatment of natalizumab-associated PML with filgrastim, PMID: 31139690
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS, PMID: 31355324
We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?, PMID: 24417188
Dosing interval of natalizumab in MS: Do good things come to those who wait?, PMID: 31515289
Natalizumab for induction of remission in Crohn's disease, PMID: 30068022
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?, PMID: 31452081
Gynecological adverse effects of natalizumab administration: Case report and review of the literature, PMID: 30032043
Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy, PMID: 27456891
Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification, PMID: 28228564
[Natalizumab], PMID: 26480703
Spanish consensus on the use of natalizumab (Tysabri®)-2013, PMID: 24360652
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study, PMID: 33082194
Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results, PMID: 33205373
Exposure to natalizumab during pregnancy and lactation is safe - Commentary, PMID: 32508210
Exposure to natalizumab during pregnancy and lactation is safe - No, PMID: 32508200
Exposure to natalizumab during pregnancy and lactation is safe - Yes, PMID: 32508253
Pharmacodynamics of natalizumab extended interval dosing in MS, PMID: 32019876
Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis, PMID: 29353737
Clinical evaluation of natalizumab for formulary consideration, PMID: 20626228
Prediction of natalizumab anti-drug antibodies persistency, PMID: 29336205
Therapeutic drug monitoring of natalizumab, PMID: 30485149
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis, PMID: 28641055
Erythroblast appearance associated with natalizumab, PMID: 30711880
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis, PMID: 31452082
Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies, PMID: 27475049
For research use only. Not for human or drug use.
